Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

48.89
-0.4850-0.98%
Volume:337.75K
Turnover:16.75M
Market Cap:5.95B
PE:-14.55
High:49.95
Open:49.52
Low:48.75
Close:49.37
52wk High:61.76
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:1.32
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:23.46
PE(LYR):-14.03

Loading ...

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
Sep 12

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS
·
Sep 12

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Sep 12

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
Sep 12

US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older

THOMSON REUTERS
·
Sep 12

Scholar Rock Holdings trading halted, news pending

TIPRANKS
·
Sep 12

NASDAQ Trade Halt Halt News Pending at 05:07 Pm

Reuters
·
Sep 12

Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 08

Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy

Reuters
·
Sep 02

Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD

Reuters
·
Sep 02

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial

THOMSON REUTERS
·
Sep 02

Scholar Rock to Present at Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Aug 27

Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Simply Wall St.
·
Aug 24

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live
·
Aug 22

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 22

Scholar Rock price target raised to $64 from $58 at Wedbush

TIPRANKS
·
Aug 21